Covid-19 roundup: Paul Hud­son says US will have first dibs on Sanofi vac­cine; Gilead se­lects 5 gener­ic man­u­fac­tur­ing part­ners for remde­sivir

If Sanofi can suc­cess­ful­ly de­liv­er a Covid-19 vac­cine, the US will get first ac­cess to it, CEO Paul Hud­son told Bloomberg News.

That’s be­cause the US, through its bio­med­ical de­fense agency BAR­DA, has in­vest­ed in the tech­nol­o­gy, back­ing the com­pa­ny’s Pro­tein Sci­ences sub­sidiary with a $30 mil­lion grant for its re­com­bi­nant Covid-19 vac­cine ef­fort. Since its found­ing in 2005, BAR­DA has heav­i­ly fund­ed both Sanofi — a French com­pa­ny — and Pro­tein Sci­ences, which was an in­de­pen­dent biotech un­til 2017.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.